Hoechst Sells Copley Stake To Teva For One-Fifth Of 1993 Purchase Price
Executive Summary
Hoechst has completed its exit from the generic pharmaceutical industry by agreeing to sell its stake in Copley to Teva-USA for $114 mil.
You may also be interested in...
WATSON TO PAY $70 MIL. UP FRONT FOR HMR's RUGBY GENERIC DIVISION; HOECHST DIVESTING GENERIC DIVISIONS BEFORE NYSE LISTING SCHEDULED FOR SEPT. 24
Watson Pharmaceuticals is paying $70 mil. up front to acquire the Rugby generic business from Hoechst Marion Roussel, the companies announced Aug. 26.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials